Securities code: 688029 Securities abbreviation: Nanwei Medical Announcement No.: 2025-007

Nanwei Medical Technology Co., Ltd

2024 Annual Results Bulletin Announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

The main financial data of Nanwei Medical Technology Co., Ltd. (hereinafter referred to as the "Company") in 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the data disclosed in the company's 2024 annual report, and investors are reminded to pay attention to investment risks.

1. Main financial data and indicators for 2024

Unit: RMB 10,000 yuan

Item Current reporting period Same period last year Change (%)

Total operating income 276,051.06 241,146.84 14.47

Operating profit 65,389.16 55,466.91 17.89

Total profit 65,942.92 56,490.99 16.73

Net profit attributable to owners of the parent company 55,166.57 48,592.43 13.53

Deductions attributable to owners of the parent company non 54,286.65 46,314.14 17.21

Net profit from recurring gains or losses

Basic earnings per share (RMB) 2.94 2.59 13.51

The weighted average return on equity was 14.94% and 14.25%, an increase of 0.69 percentage points

End of the reporting period Beginning of the reporting period Change of change (%)

Total assets 475,936.77 439,267.30 8.35

Owners' equity attributable to parent company 383,102.50 361,191.99 6.07

Share capital 18,784.74 18,784.74 -

Net per share attributable to owners of the parent company 20.39 19.23 6.07

Assets (RMB)

Note: The opening figures of this reporting period are the same as the year-end figures of the previous year as disclosed by law. The above financial data and indicators are filled in with consolidated financial statements, but are unaudited, and the final results are subject to the company's 2024 annual report. If there is a penny difference in the data, it is due to rounding.

2. Explanation of operating performance and financial situation

(1) A description of the operating situation and financial situation of the reporting period.

In the face of the complex situation at home and abroad, the company has the courage to meet the challenges, adheres to independent research and development, medical and engineering innovation and industry-university-research cooperation, continuously deepens the domestic marketing market, further expands the coverage of overseas channels, continuously optimizes and transforms production and operation methods, and maintains a good momentum of stable and sustainable development.

In 2024, the company achieved a total operating income of 2760.5106 million yuan, an increase of 14.47% over the same period of the previous year; net profit attributable to owners of the parent company was 551.6657 million yuan, an increase of 13.53% over the same period of last year; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 542.8665 million yuan, an increase of 17.21% over the same period of last year.

At the end of the reporting period, the company's financial position was good, with total assets of 4759.3677 million yuan, an increase of 8.35% over the beginning of the reporting period; The owner's equity attributable to the parent company was 383,102.50 million yuan, an increase of 6.07% from the beginning of the reporting period.

3. Risk Warning

The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the data disclosed in the company's 2024 annual report.

The announcement is hereby made.

Board of Directors of Nanwei Medical Technology Co., Ltd

February 25, 2025